Literature DB >> 16728076

Equine arteritis virus.

A L Glaser1, E D Chirnside, M C Horzinek, A A de Vries.   

Abstract

Equine arteritis virus (EAV) is a small, enveloped, positive-stranded RNA virus, in the family Arteriviridae , W.H.ich can infect both horses and donkeys. While the majority of EAV infections are asymptomatic, acutely infected animals may develop a wide range of clinical signs, including pyrexia, limb and ventral edema, depression, rhinitis, and conjunctivitis. The virus may cause abortion and has caused mortality in neonates. After natural EAV infection, most horses develop a solid, long-term immunity to the disease. Marzz and geldings eliminate the virus within 60 days, but 30 to 60% of acutely infected stallions will become persistently infected. These persistently infected animals maintain EAV within the reproductive tract, shed virus continuously in the semen, and can transmit the virus venereally. Mares infected venereally may not have clinical signs, but they shed large amounts of virus in nasopharyngeal secretions and in urine, which may result in lateral spread of the infection by an aerosol route. The consequences of venereally acquired infection are minimal, with no known effects on conception rate, but mares infected at a late stages of gestation may abort. Identification of carrier stallions is crucial to control the dissemination of EAV. The stallions can be identified by serological screening using a virus neutralization (VN) test. If positive at a titer of >/= 1:4, the stallion should be tested for persistent infection by virus isolation from the sperm-rich fraction of the ejaculate, or by test mating Shedding stallions should not be used for breeding, or should be bred only to mares seropositive from a natural infection or from vaccination, the mares should be subsequently isolated from seronegative horses for three weeks after natural or artificial insemination. A live attenuated (ARVAC) and a formalin-inactivated (ARTERVAC) vaccine are available. Both vaccines induce virus-neutralizing antibodies, the presence of which correlates with protection from disease, abortion, and the development of a persistent infection. Serological investigations indicate that EAV has a worldwide distribution and that its prevalence is increasing. As a consequence, an increasing number of equine viral arteritis (EVA) outbreaks is being reported. This trend is likely to continue unless action is taken to slow or halt the transmission of this agent through semen.

Entities:  

Year:  1997        PMID: 16728076      PMCID: PMC7127492          DOI: 10.1016/s0093-691x(97)00107-6

Source DB:  PubMed          Journal:  Theriogenology        ISSN: 0093-691X            Impact factor:   2.740


  61 in total

1.  Fatal, congenitally acquired infection with equine arteritis virus in a neonatal thoroughbred.

Authors:  W E Vaala; A N Hamir; E J Dubovi; P J Timoney; B Ruiz
Journal:  Equine Vet J       Date:  1992-03       Impact factor: 2.888

2.  Ontario. Equine arteritis virus isolated from a Standardbred foal with pneumonia.

Authors:  S Carman; C Rae; E Dubovi
Journal:  Can Vet J       Date:  1988-11       Impact factor: 1.008

3.  Equine arteritis virus-induced polypeptide synthesis.

Authors:  M F van Berlo; P J Rottier; W J Spaan; M C Horzinek
Journal:  J Gen Virol       Date:  1986-08       Impact factor: 3.891

4.  Natural equine viral arteritis in foals.

Authors:  W Golnik; Z Michalska; T Michalak
Journal:  Schweiz Arch Tierheilkd       Date:  1981-10       Impact factor: 0.845

5.  Use of the serum neutralisation test for equine viral arteritis with different virus strains.

Authors:  Y Fukunaga; T Matsumura; T Sugiura; R Wada; H Imagawa; T Kanemaru; M Kamada
Journal:  Vet Rec       Date:  1994-05-28       Impact factor: 2.695

6.  The effects of vaccination with tissue culture-derived viral vaccines on detection of antibodies to equine arteritis virus by enzyme-linked immunosorbent assay (ELISA).

Authors:  R F Cook; S J Gann; J A Mumford
Journal:  Vet Microbiol       Date:  1989-06       Impact factor: 3.293

7.  Identification of a neutralization site in the major envelope glycoprotein (GL) of equine arteritis virus.

Authors:  U B Balasuriya; N J Maclachlan; A A De Vries; P V Rossitto; P J Rottier
Journal:  Virology       Date:  1995-03-10       Impact factor: 3.616

8.  Equine arteritis virus-neutralizing antibody in the horse is induced by a determinant on the large envelope glycoprotein GL.

Authors:  E D Chirnside; A A de Vries; J A Mumford; P J Rottier
Journal:  J Gen Virol       Date:  1995-08       Impact factor: 3.891

9.  Comparison of equine arteritis virus isolates using neutralizing monoclonal antibodies and identification of sequence changes in GL associated with neutralization resistance.

Authors:  A L Glaser; A A de Vries; E J Dubovi
Journal:  J Gen Virol       Date:  1995-09       Impact factor: 3.891

10.  Development and evaluation of an ELISA using recombinant fusion protein to detect the presence of host antibody to equine arteritis virus.

Authors:  E D Chirnside; P M Francis; A A de Vries; R Sinclair; J A Mumford
Journal:  J Virol Methods       Date:  1995-07       Impact factor: 2.014

View more
  4 in total

1.  Development and characterization of an infectious cDNA clone of the modified live virus vaccine strain of equine arteritis virus.

Authors:  Jianqiang Zhang; Yun Young Go; Chengjin M Huang; Barry J Meade; Zhengchun Lu; Eric J Snijder; Peter J Timoney; Udeni B R Balasuriya
Journal:  Clin Vaccine Immunol       Date:  2012-06-27

2.  Genetic divergence with emergence of novel phenotypic variants of equine arteritis virus during persistent infection of stallions.

Authors:  J F Hedges; U B Balasuriya; P J Timoney; W H McCollum; N J MacLachlan
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Genetic typing of equine arteritis virus isolates from Argentina.

Authors:  María Gabriela Echeverría; Silvina Díaz; Germán Ernesto Metz; María Soledad Serena; Carlos Javier Panei; Edgardo Nosetto
Journal:  Virus Genes       Date:  2007-02-09       Impact factor: 2.332

4.  Antiviral activity of carbohydrate-binding agents against Nidovirales in cell culture.

Authors:  F J U M van der Meer; C A M de Haan; N M P Schuurman; B J Haijema; W J Peumans; E J M Van Damme; P L Delputte; J Balzarini; H F Egberink
Journal:  Antiviral Res       Date:  2007-05-21       Impact factor: 5.970

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.